0.975
-0.07 (-6.25%)
AIStockmoo Score
| Value 30% | -2.1 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Earns below its cost of capital. Returns on capital falling. info | |
| Timing 30% | -4.1 |
| From our AI technical analysis of the chart. info | NA |
| Downtrend over the past year. Far below its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| News Mood info | NA |
| Smart Money 20% | -1.4 |
| Insider Activity info | NA |
| Institutions net -0.52% of shares in their latest 13F filings: 23 holders increased, 18 decreased (quarter to 30 Sep 2026). info | |
| Short interest +39.2% from 31 Aug to 30 Oct 2026, 5.5 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| Price is near support. Levels trending down. info | |
| Final Score | -2.99 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Gain Therapeutics, Inc. | Mixed | Mixed |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| GANX | - | - | - | 4.54 |
| TRML | 1 B | - | - | 4.76 |
| TECH | - | 0.44% | - | 5.28 |
| MLTX | - | - | - | 2.79 |
| VKTX | - | - | - | 6.33 |
| VSTM | - | - | - | 76.50 |
Select this tab to load the latest available analysis.
|
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.78% |
| % Held by Institutions | 8.14% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cambridge Investment Research Advisors, Inc. | 30 Sep 2026 | 566,645 |
| Dme Capital Management, Lp | 30 Jun 2026 | 566,130 |
| Cresset Asset Management, Llc | 30 Jun 2026 | 160,000 |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 20.51%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 23 | 865,600 |
| Decreased | 18 | 1,105,450 |
| New | 11 | 427,858 |
| Sold out | 6 | 422,295 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 3,891,227 | 5.5 |
| 15 Oct 2026 | 3,191,453 | 6.5 |
| 30 Sep 2026 | 3,056,188 | 5.9 |
| 15 Sep 2026 | 2,887,151 | 8.9 |
| 31 Aug 2026 | 2,795,819 | 7.7 |
| 14 Aug 2026 | 2,952,391 | 4.9 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 16 Nov 2026 | Yahoo Finance |
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know
Gain Therapeutics (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
| 10 Nov 2026 | Yahoo Finance |
Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
BETHESDA, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the… |
| 05 Nov 2026 | Yahoo Finance |
Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
BETHESDA, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of two… |
| 08 Oct 2026 | Yahoo Finance |
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small-molecule therapies, today announced it will participate in the… |
| 01 Oct 2026 | Yahoo Finance |
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by August 31, 2026 Participants with both high and low baseline levels of GluSph… |
| 29 Sep 2026 | Yahoo Finance |
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at… |
| 17 Sep 2026 | Yahoo Finance |
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President… |
| 25 Aug 2026 | Yahoo Finance |
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President… |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |